Literature DB >> 11126855

Emergency postcoital contraception.

R E Wertheimer1.   

Abstract

Emergency postcoital contraception, a method used to prevent pregnancy after unprotected sexual intercourse, is a highly effective but underutilized birth control option. Two hormone regimens, ethinyl estradiol (100 microg) with levonorgestrel (0.5 mg) or high-dose levonorgestrel (0.75 mg), given within 72 hours of intercourse and repeated 12 hours later, are available for this purpose. These regimens are packaged as Food and Drug Administration labeled, dedicated products or can be adapted for use from standard oral contraceptive pills. Emergency postcoital contraception should be considered as a primary prevention health service to women of childbearing age.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11126855

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  5 in total

Review 1.  [Emergency contraception].

Authors:  I Lete Lasa; M Arróniz; R Esquisábel
Journal:  Aten Primaria       Date:  2001-06-15       Impact factor: 1.137

Review 2.  [After levonorgestrel, will mifepristone (RU486) be the next day-after pill?].

Authors:  F López De Castro; N Campos Campos; S Castillo Portales; F Rodríguez Alcalá
Journal:  Aten Primaria       Date:  2001-03-31       Impact factor: 1.137

Review 3.  Emerging options for emergency contraception.

Authors:  Atsuko Koyama; Laura Hagopian; Judith Linden
Journal:  Clin Med Insights Reprod Health       Date:  2013-02-18

4.  Emergency contraception: knowledge and attitudes of family physicians of a teaching hospital, Karachi, Pakistan.

Authors:  Hamza M Abdulghani; Syed I Karim; Farhana Irfan
Journal:  J Health Popul Nutr       Date:  2009-06       Impact factor: 2.000

5.  Women's attitudes towards mechanisms of action of family planning methods: survey in primary health centres in Pamplona, Spain.

Authors:  Jokin de Irala; Cristina Lopez del Burgo; Carmen M Lopez de Fez; Jorge Arredondo; Rafael T Mikolajczyk; Joseph B Stanford
Journal:  BMC Womens Health       Date:  2007-06-27       Impact factor: 2.809

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.